Physician profile

Mark Ryan Rowe

Family Medicine · Colorado Springs, CO

NPI 1770922510

$2,616.68

in general payments reported to CMS, 2019-2025

47 companies · $722 in 2025

The $722 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,476.92

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $322.65 2020-2025 Airsupra, Tezspire
Inspire Medical Systems, INC. $195.21 2023-2024 Inspire
Novo Nordisk INC $189.61 2020-2025 Rybelsus, Ozempic, Wegovy
Amgen INC. $157.36 2020-2025 Otezla, Repatha, Otezla
Abbvie INC. $120.55 2021-2025
Boston Scientific Corporation $97.40 2022-2025 Wavewriter Alpha Prime 16, Accolade Sr
Exact Sciences Corporation $91.09 2024-2025 Cologuard Collection Kit
Lilly USA, LLC $83.64 2021-2025 Mounjaro, Zepbound
Pfizer INC. $76.70 2021-2025
Xeris Pharmaceuticals, INC. $60.81 2025 Keveyis, Gvoke Hypopen
Paratek Pharmaceuticals, INC. $57.92 2021
Hologic Sales and Service, LLC $56.45 2022-2023 Thinprep 2000 Processor, Aptima
Alexion Pharmaceuticals, INC. $54.50 2020-2022
Edwards Lifesciences Corporation $53.73 2022-2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Merck Sharp & Dohme LLC $50.04 2021-2022
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Alkermes, INC. $49.68 2024 Aristada, Lybalvi
Daiichi Sankyo INC. $49.59 2020-2021
Bayer Healthcare Pharmaceuticals INC. $48.93 2022
E.R. Squibb & Sons, L.L.C. $43.63 2020-2021
Astellas Pharma US INC $43.24 2025 Veozah
Teva Pharmaceuticals USA, INC. $43.18 2023-2024 Austedo Xr
Takeda Pharmaceuticals U.S.A., INC. $41.01 2021-2025 Trintellix
Boehringer Ingelheim Pharmaceuticals, INC. $39.63 2020-2021
Aimmune Therapeutics, INC. $39.26 2024-2025 Zenpep
Novartis Pharmaceuticals Corporation $38.87 2022-2025
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $38.63 2022
Medtronic, INC. $37.38 2022-2025 Symplicity G3
Abbott Laboratories $33.32 2021-2025 Eterna
Neurocrine Biosciences, INC. $32.92 2021-2024 Ingrezza
Optinose US, INC. $31.45 2021
Janssen Pharmaceuticals, INC $30.24 2021
Dexcom, INC. $28.91 2023-2024 Dexcom G6 Transmitter
Abiomed $27.00 2025
Nestle Healthcare Nutrition INC. $25.25 2021
Ibsa Pharma INC. $22.35 2025 Licart, Flector, Tirosint
Sanofi-Aventis U.S. LLC $22.32 2025
Genzyme Corporation $19.63 2025
Ultragenyx Pharmaceutical INC. $19.40 2021
Actelion Pharmaceuticals US, INC. $19.25 2025 Opsumit, Uptravi
Lundbeck LLC $19.09 2023 Rexulti
Vbi Vaccine (Delaware) INC. $17.28 2022
Glaxosmithkline, LLC. $17.00 2021
Axsome Therapeutics, INC. $15.65 2023 Sunosi
Esperion Therapeutics, INC. $15.45 2020
Idorsia Pharmaceuticals US INC $14.26 2023 Quviviq
Currax Pharmaceuticals LLC $13.69 2025 Contrave
Genentech USA, INC. $11.53 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Ryan Rowe

$2,616.68

in general payments reported 2019-2025

Years
2020-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $722 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/1613854/mark-ryan-rowe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.